Aditya Ghodke’s Post

#fundingalert 💼Company: HEPHAISTOS-Pharma 💰Funding: €4.5 Million ⚡Round: Seed 👥Investors: Elaia, xista science ventures, the Fondation Fournier-Majoie and Noshaq. HEPHAISTOS-Pharma is a preclinical biotech company developing the next generation of #immunostimulants against cancer, revolutionizing immune stimulation targeting innate immunity with a unique technology for intravenous administration, opening the way to metastatic and hard-to-treat indications. This seed round will mainly #finance the industrialization of drug production and regulatory toxicity studies to file for the CTA in Europe. HEPHAISTOS already has a lot of preclinical data in many cancer indications, but they plan to generate new additional data in monotherapy against unmet medical needs and in combination with promising drugs from other pharmaceutical companies. Frederic CAROFF, Florian Denis, Martine Caroff, Alexey Novikov Read more - https://lnkd.in/gYkPH4mH To share your startup story write us on - contact@startuprise.co.uk #HEPHAISTOSPharma #biotechstartup #revolutionizing #monotherapy #pharmaceutical #funding #fundingnews #news #startup #startupnews #startuprise

🔬Messaginglab and Degron Therapeutics Partnered on a $1.2B Collaboration Announcement - With Big Results 🧬 We're thrilled to have collaborated with Degron Therapeutics - an emerging leader in the discovery of small molecule, molecular glue degrader drugs - on their recent press release announcing their $1.2B collaboration with Takeda. Molecular glue degraders are small molecule drugs that act as adhesives by bringing a disease target protein to another protein called E3 ligase, which is a component of a protein degradation machinery. As a result, the disease target protein is “tagged” as trash and degraded in the cell.   This approach has the potential to target previously undruggable proteins, opening new avenues for treating challenging diseases in cancer, inflammation, neurodegenerative and other disorders. Messaginglab's Impact: 💡Translating Difficult Science: We simplified the complexity of molecular glues to help Degron reach a broader audience. Our approach resonated widely for investors, partners, and the public. 💡Amplifying Media Presence: Through targeted outreach, we secured coverage in 20 top life science and pharma publications, including Biocentury, BioWorld, Chemical & Engineering News, and Fierce Biotech. This expanded visibility positioned Degron as a key player in biotech. 💡Crafting a Compelling Corporate Narrative: Beyond the $1.2B deal, we highlighted Degron's mission to revolutionize drug discovery. We created an emotional connection by focusing on the impact on patients' lives, elevating Degron's story above financial metrics. 💡Showcasing Thought Leadership: We positioned Degron's co-founder and CEO, Lily Zou, as a visionary leader. Her quotes and media accessibility added a human touch to the company's technological breakthroughs, building trust and credibility. 💡Driving Meaningful Engagement: Our success went beyond metrics. We focused on generating high-quality media coverage that sparked conversations among key stakeholders in the biotech community. The Power of Partnership: We're proud to have been a part of this groundbreaking work. Our collaboration with Degron Therapeutics showcases Messaginglab's ability to elevate complex science through strategic communication. #MediaRelations #BiopharmaNews

How hot is biotech right now? Look at these Massachusetts launches and raises in just the last few days: Passkey Therapeutics (Cambridge, MA) emerges from stealth with $20 million to develop an approach toward single drugs for multiple proteins. (Rowan Walrath in C&EN: https://lnkd.in/eeXn9r9K) Treeline Biosciences, with offices in Watertown, discloses another $421.8 million. (Hannah Green in Boston Business Journal: https://lnkd.in/eecnb_ZK) AvenCell Therapeutics (Watertown, MA) has secured $112 million in series B funds as it seeks clinical proof that it can generate CAR-T cells that can be turned “on” once inside a patient. (James Waldron in Fierce Biotech: https://lnkd.in/edW2wxtw) 🔥 According to Endpoints News, there have been 80 nine-figure private financings this year in the biotech industry nationally.

10 Noteworthy Global Biotech Companies that Got Funded in the first Quarter of 2024 According to data sourced from Crunchbase, the funding for Biotech companies represents a 161 percent upsurge compared to the USD 1.1 billion raised by the largest funding rounds which involved healthcare-focused biotech companies in the first quarter of 2023. Read the full article: https://goo.su/HCqWR By Samrat Pradhan, Managing Editor, #FinanceOutlookIndia Zephyr AI Yiyuan Yin FogPharma Mike Nolan Andrew Chi Baiteng Zhao Tubulis GmbH Laura Shawver Rakuten Medical Clasp Therapeutics Greg Chow, Freenome Diagonal Therapeutics Jixing Pharmaceuticals Obsidian Therapeutics Alamar Biosciences, Inc. ARS Pharmaceuticals, Inc. Nadia Agopyan, Ph.D., RAC Mark M, Sionna Therapeutics BlossomHill Therapeutics, Inc. BJ Sullivan, PhD, BioAge Labs Catherine Priest, Neurona Therapeutics #GlobalBiotech #FirstQuarter2024 #Biotechnologyindustry #FundingRounds #EmergingBiotechFirms #VentureCapital #TechnologicalAdvances #InnovationSpotlight

Stories making headlines today in the biopharma industry: Ironwood Pharmaceuticals' stock has taken a major hit with a 40% drop owing to ambiguous outcomes of the Phase III STARS clinical trial of Apraglutide, their short bowel syndrome drug. The drug met its primary endpoint but fell short of significantly impacting secondary outcomes. In another update, Orbis Medicines, a start-up dedicated to creating peptide drugs thanks to macrocycles, has been successful in accruing €26 million in seed funding. Prominent European VC funds Forbion and Novo Holdings provided this initial financial push. Macrocycles are gaining investor attention thanks to improvements in peptide design methods. San Diego-based biotech venture, BlossomHill Therapeutics, has also been fortunate in the fund-raising realm, amassing an incredible $100 million in Series B investment. This huge financial incentive will enable the integration of three oncology small molecules into clinical trials and facilitate swift gathering of preliminary efficiency data by H2 2025. The venture was initiated in 2020 by ex-Turning Point Therapeutics co-founders J. Jean Cui and Y. Peter Li. The philanthropic venture, Chan Zuckerberg Initiative (CZI), has revealed that it's funding four basic biology research networks. These multi-year grant packages, averaging $14 million over three years, will directly benefit universities in their quest to examine RNA and protein networks in cells, bypassing traditional government finance channels that often sideline unpredictable research initiatives. Lastly, Kenai Therapeutics has procured $82 million in financial backing for their dedicated Parkinson's disease research. The fund will escalate efforts to unveil the cure for this critical disease and save many lives in the near future. #pharma #biotech #topstories #biodatastudio

Alumis, an 𝐢𝐦𝐦𝐮𝐧𝐨𝐥𝐨𝐠𝐲 𝐛𝐢𝐨𝐭𝐞𝐜𝐡 on the cusp of 𝐏𝐡𝐚𝐬𝐞 𝟑, has secured $𝟐𝟓𝟎𝐌 𝐢𝐧 𝐚 𝐬𝐡𝐫𝐮𝐧𝐤𝐞𝐧 𝐈𝐏𝐎. The Bay Area startup sold 𝟏𝟑.𝟏𝟐 𝐦𝐢𝐥𝐥𝐢𝐨𝐧 𝐬𝐡𝐚𝐫𝐞𝐬 𝐚𝐭 $𝟏𝟔 𝐞𝐚𝐜𝐡 to fund the late-stage testing of its lead 𝐓𝐘𝐊𝟐 𝐝𝐫𝐮𝐠, studies of a second asset in neuroinflammatory conditions, and preclinical projects. While the IPO was smaller than initially projected, an additional 𝟐.𝟓 𝐦𝐢𝐥𝐥𝐢𝐨𝐧 𝐬𝐡𝐚𝐫𝐞𝐬 were sold in a concurrent private placement. With $𝟑𝟒𝟓 𝐦𝐢𝐥𝐥𝐢𝐨𝐧 𝐚𝐥𝐥𝐨𝐜𝐚𝐭𝐞𝐝 toward clinical development, Alumis aims to create a next-gen immunology treatment, facing competition from Bristol Myers Squibb’s Sotyktu and Takeda’s TAK-279. Alumis has spent heavily on R&D, with $𝟏𝟑𝟕 𝐦𝐢𝐥𝐥𝐢𝐨𝐧 𝐥𝐚𝐬𝐭 𝐲𝐞𝐚𝐫 𝐚𝐧𝐝 $𝟏𝟎𝟏 𝐦𝐢𝐥𝐥𝐢𝐨𝐧 𝐢𝐧 𝟐𝟎𝟐𝟐. The company, led by Martin Babler, hopes to buck the trend of biotechs trading below their IPO price. https://lnkd.in/eK_H6kda #Biotech #Immunology #IPO #Pharma #HealthcareInnovation

It’s time to find out who bagged the biggest private biotech investments in June 2024! 💰 The biggest funding rounds went to the companies Formation Bio, ITM Isotope Technologies Munich SE, and Marea Therapeutics. 📈 Meanwhile, around the world, oncology and central nervous system players attracted the biggest funding rounds overall. 🌍 Read our latest article to find out more about biotech’s biggest private investments in June, as we break down the investments by location and funding type, and compare June’s fundraising to previous months. 💡 https://lnkd.in/dYvuBVt9 #biotechinvestments #oncologyresearch #biotechfunding #healthcareinnovation #investmenttrends #globalbiotech #lifesciences Santa Ana Bio, Inc. | Alzheon, Inc. | Preserving Future Memories | Bright Peak Therapeutics | iOnctura | InduPro | Exsilio Therapeutics | Elion Therapeutics | Enveda Biosciences | Iambic Therapeutics | Spur Therapeutics | āshibio, Inc | Adcytherix | Envisagenics | Vilya | Frontier Medicines | Augustine Therapeutics | GPN Vaccines

🔵🔴⚪𝗖𝗲𝗹𝗹 𝘁𝗵𝗲𝗿𝗮𝗽𝘆 𝘄𝗶𝘁𝗵𝗼𝘂𝘁 𝗰𝗲𝗹𝗹𝘀': 𝗖𝗮𝗽𝘀𝘁𝗮𝗻 𝗿𝗮𝗶𝘀𝗲𝘀 $𝟭𝟳𝟱𝗠 𝘁𝗼 𝘁𝗲𝘀𝘁 𝗶𝗻 𝘃𝗶𝘃𝗼 𝗖𝗔𝗥-𝗧 Laura Shawver pictures a world 10 years from now where cell therapies are replaced by in vivo CAR-T products. The goal is a cheaper-to-produce, less complex and more accessible cell therapy. Capstan Therapeutics, a biotechnology startup developing medicines that reprogram cells inside the body, has raised another $175 million to bring its first prospect into clinical testing. Capstan’s goal is to use messenger RNA technology to coax the body into making its own CAR-T cells. The high-profile startup, formed by a group of pioneering cell therapy and messenger RNA researchers, secured the financing from a wide range of investors led by RA Capital and including five pharmaceutical companies, it said Wednesday. Johnson & Johnson is one of Capstan’s new backers, joining existing investors Pfizer, Bristol Myers Squibb, Eli Lilly and Company and Bayer, among others. The startup has now raised $340 million since 2021.  Learn more : https://lnkd.in/eH6JKt8N #celltherapy #innovation

Happy to announce LongeVC invested in CatenaBio, a biotech startup that transforms the design of biologic drugs. CatenaBio is spun out of Berkeley Lab famous for the discovery of CRISPR by Dr Jennifer Doudna and her colleagues. We have contributed to the startup’s seed extension round with a raise of $2.35M. What is cool about CatenaBio is their quite transformative vision for biology. Let’s unpack it. As you probably know, traditional drug discovery is mostly focused on small molecules -- low molecular weight compounds often synthesized chemically. Aspirin and Ibuprofen are good examples here. Such drugs can be very potent. The issue with many small molecule-based drugs is that they are kind of "promiscuous" actors, which may affect many targets and render off-target effects. They are a “one-size-fits-all” kind of drugs. In contrast, biological drugs, or biologics, are large biomolecules, like antibodies. They are extremely specific to their targets, so have little-to-no off-target effects. Going further, a very powerful and innovative combination is so called conjugates, when biologics are combined with small molecules or other drug modalities to create powerful and very targeted drugs at the same time. In this case, the best of both worlds (chemistry and biology) is utilized, so to speak. Great example here is a very dynamic area of antibody-drug conjugates (ADCs) -- they are exceptionally promising in fighting age-related diseases, cancer and so on. But CatenaBio goes even further than that! In classical ADCs there is only one drug “warhead” and so there is limitation in treatment possibilities. CatenaBio is developing Multi-Payload Conjugate (MPC) technology by combining two payloads with different mechanisms of action (MOAs) on a single antibody. CatenaBio’s technology also allows combining various biologics. The result is the ability to synthesize novel biomolecules in any structure, combination, or orientation—the only limitation is imagination. I believe this company is creating a new world of drug discovery and I am glad we are contributing to this future! #biotech #drugdiscovery #venturecapital Image credit: CatenaBio

✨ Leading innovation: 10 promising European startups focusing on biopharmaceuticals 🇪🇺 The biopharmaceutical industry in Europe is seeing significant innovation, with several startups making breakthroughs in drug development and healthcare technologies. 🏆 Here is a list of the 10 Promising European Biotech Startups:- 1.) Vivoryon Therapeutics N.V. Therapeutics: Focuses on developing small molecule drugs for severe diseases, leveraging deep knowledge of disease pathways. 2.) Allecra Therapeutics: Aims to combat antibiotic resistance with its lead product, cefepime/enmetazobactam, which has shown promise in global Phase 3 trials. 3.) Rentschler Biopharma SE: Specializes in biopharmaceutical process development and manufacturing, ensuring high-quality solutions. 4.) Atriva Therapeutics GmbH: Develops antiviral therapies targeting host mechanisms to reduce viral replication and resistance. 5.) GQ Bio Therapeutics: Innovates in gene therapy for conditions like osteoarthritis, using its HCAd gene therapy vector. 6.) c-LEcta GmbH: Provides enzyme products for food and pharmaceutical industries using its proprietary ENESYZ® platform. 7.) Phenex Pharmaceuticals AG Pharmaceuticals: Focuses on small-molecule drug discovery for liver diseases and cancer. 8.) Thermosome: Uses heat-sensitive liposomal formulations for targeted cancer therapy. 9.) Sysmex Inostics: Pioneers ctDNA mutation detection technologies for precision diagnostics. 10.) Formycon AG: Develops biosimilars to expand access to affordable medicines. These startups represent a dynamic and rapidly evolving sector, poised to address some of the most pressing challenges in healthcare through innovative solutions. ✨ For more details, you can read the full article on EU-Startups 👇 https://lnkd.in/dVeUhW8p #healthcare #bio_pharmaceuticals #drug #medicine #medical #tech #biotech #Cancer #Liver #genetherapy #innovation #innovators #European #startups #founder #investor #VCs #investment #entrepreneur #angelinvestor #future #funding #success #opportunity #invest #SMEs #entrepreneurship